Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Eli Lilly and Company1 site in 1 country440 target enrollmentJune 2005

ConditionsAttention Deficit Hyperactivity Disorder Comorbid Social Anxiety Disorder

DrugsAtomoxetine hydrochloride placebo

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Attention Deficit Hyperactivity Disorder
Sponsor: Eli Lilly and Company
Enrollment: 440
Locations: 1
Primary Endpoint: Reduction in signs and symptoms of ADHD as measured by the mean changes from baseline to endpoint in Conner's adult ADHD rating scale
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder

Registry

clinicaltrials.gov

Start Date

June 2005

End Date

May 2007

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

•You must be 18 to 65 years old.
•You must have been diagnosed with attention deficit hyperactivity disorder and social anxiety disorder.
•You must be able to visit the doctor's office at least 8 times over a 16 week period.
•You must agree to participate with all tests and examinations that are required for this study.

Exclusion Criteria

•You are a woman and pregnant or breastfeeding.
•You presently have an acute or unstable medical illness.
•You have a history of allergic reaction to atomoxetine hydrochloride.
•You are taking medications that are not permitted in this study. Your physician will discuss these with you.
•You have taken part in another clinical research trial within the last 30 days or have received treatment with a drug in the last 30 days that has not received regulatory approval.